Skip to Content

Join the 'Necitumumab' group to help and get support from people like you.

Necitumumab News

Many Cancer Patients Skimp on Treatment Due to Cost

Posted 24 Oct 2017 by Drugs.com

TUESDAY, Oct. 24, 2017 – The high cost of cancer care in the United States has led more than one-quarter of patients to cut back on some part of their treatment, a new survey reveals. Commissioned by the American Society of Clinical Oncology (ASCO), the report found that 27 percent of cancer survivors or close relatives of a cancer patient said they'd skipped doctor visits or taken other steps to reduce health costs. To save money, nearly one in 10 said they had avoided doctor appointments. Eight percent had refused treatment; postponed filling or not filled prescriptions; or skipped doses of prescribed medications. And 7 percent said they had cut pills in half, according to the survey of more than 4,000 adults. Such measures can jeopardize treatment success, ASCO says. "We should all be alarmed that Americans are potentially risking not only their health, but also their lives, due to ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Methotrexate, Breast Cancer, Lupron, Medroxyprogesterone, Tamoxifen, Arimidex, Fluorouracil, Lupron Depot, Femara, Gleevec, Colorectal Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Anastrozole, Votrient, Letrozole, Tarceva

Treatment Costs Can Be Another Blow to Cancer Patients

Posted 27 Jul 2017 by Drugs.com

THURSDAY, July 27, 2017 – The emotional and physical costs of cancer can be staggering. But the financial side of cancer is also a great burden, with many patients in the United States struggling to pay for treatment, new research reveals. "The current health law has greatly improved access to meaningful health coverage for cancer patients, survivors and all those with chronic diseases," Chris Hansen, president of the American Cancer Society Cancer Action Network, said in a network news release. "Yet costs remain a challenge for those facing cancer. Our country and our lawmakers should come together to find bipartisan solutions that begin to address patient costs without sacrificing the quality of coverage," he urged. Researchers surveyed financial navigators at 11 hospitals in nine states. Financial navigators – typically trained social workers or nurses – help cancer patients ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Breast Cancer, Lupron, Prostate Cancer, Medroxyprogesterone, Tamoxifen, Arimidex, Lupron Depot, Femara, Gleevec, Lung Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Anastrozole, Brain Tumor, Skin Cancer, Letrozole, Tarceva

More Patients OK'd for Cancer Trials Under Obamacare: Study

Posted 20 Jul 2017 by Drugs.com

THURSDAY, July 20, 2017 – The Affordable Care Act has enabled more privately insured patients to enroll in clinical trials for new cancer treatments, a new study contends. Speedy approvals are important for patients who want to participate in clinical trials, said study author Dr. David Hong. He's deputy chair of investigational cancer therapeutics at the University of Texas MD Anderson Cancer Center. Since 2000, Medicare, the publicly funded insurance program for seniors, has covered routine costs of clinical trial participation. But coverage for patients with private insurance differed by insurer and state, the researchers noted. Under the ACA, or Obamacare, however, private insurers had to cover "standard of care" costs of clinical trial participation as of 2014. For this study, the researchers analyzed more than 2,400 patient referrals to the Clinical Center for Targeted Therapy at ... Read more

Related support groups: Cancer, Breast Cancer, Prostate Cancer, Gleevec, Colorectal Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Votrient, Tarceva, Avastin, Tasigna, Sprycel, Pancreatic Cancer, Sutent, Afinitor, Nexavar, Cisplatin, Carboplatin, Head and Neck Cancer, Erbitux

Publicly Funded Cancer Trials Gained Americans 3 Million More Years

Posted 6 Jun 2017 by Drugs.com

TUESDAY, June 6, 2017 – Public-funded trials have significantly extended the lives of people diagnosed with cancer, according to new research. SWOG, the clinical trials network funded by the U.S. National Cancer Institute (NCI), has involved more than 200,000 patient volunteers. These trials have led to approval of 14 new cancer drugs and more than 100 changes to cancer care standards. All told, the clinical trials studied extended life by 3.34 million years, the study found. SWOG estimates the dollar return on investment from federal funding at $125 for each year of life gained. "A lot of people with cancer have lived longer because of the therapies tested in our publicly funded trials," study leader Joseph Unger said in a SWOG news release. He is an assistant member of the Fred Hutchinson Cancer Research Center's Cancer Prevention Program in Seattle. "At the same time, the cost of ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Prostate Cancer, Medroxyprogesterone, Tamoxifen, Tretinoin, Fluorouracil, Arimidex, Lupron Depot, Femara, Gleevec, Colorectal Cancer, Lung Cancer, Rituxan, Isotretinoin

Cancer's Heavy Financial Burden

Posted 8 Jun 2016 by Drugs.com

WEDNESDAY, June 8, 2016 – Many cancer patients can't afford to see their doctor or take the medications they've been prescribed, a new study finds. And the problem will likely only get worse as the cost of cancer treatments continues to rise, the study authors said. "You can prescribe the best drug in the world, but if patients can't afford it and they can't get it, then it won't be effective," said study author Dr. Greg Knight. He is chief fellow with the University of North Carolina School of Medicine's division of hematology and oncology. "We saw a significant portion of patients in our study who were stretching their prescriptions or not coming to the doctor's office," Knight said in a university news release. The researchers reviewed survey results from nearly 2,000 patients at the N.C. Cancer Hospital in Chapel Hill, N.C. The participants were all 18 and older, and had been ... Read more

Related support groups: Cancer, Breast Cancer, Prostate Cancer, Gleevec, Lung Cancer, Colorectal Cancer, Votrient, Brain Tumor, Skin Cancer, Tarceva, Melanoma, Ovarian Cancer, Nausea/Vomiting - Chemotherapy Induced, Avastin, Tasigna, Endometrial Cancer, Sprycel, Sutent, Herceptin, Afinitor

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less able to afford cancer drugs than Americans, he said, even though U.S. monthly drug prices are about three to six times higher in the United States. That doesn't mean America came out on top in overall drug affordability, however. Developed nations such as Australia, England and Israel had the "best deal" in the world on cancer drugs, thanks to government programs that regulate drug pricing, the study found. "America is the wealthiest nation, but its drug prices are significantly higher – so much ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Medroxyprogesterone, Tamoxifen, Tretinoin, Arimidex, Fluorouracil, Lupron Depot, Femara, Gleevec, Lung Cancer, Colorectal Cancer, Isotretinoin, Rituxan, Anastrozole

'Precision' Cancer Treatment May Extend Lives

Posted 20 May 2016 by Drugs.com

THURSDAY, May 19, 2016 – "Precision" cancer treatment that's guided by genetic clues from the patient's own tumor appears to outperform traditional chemotherapy, a new research review finds. Patients given precision – or personalized – treatment experienced a tumor shrinkage rate six times that attained by regular chemotherapy. But, that only happened if doctors used genetic information to choose the appropriate targeted therapy, said lead researcher Maria Schwaederle. Those patients also experienced nearly double the length of time before their cancer resumed growing, according to the analysis of nearly 350 clinical trials. "It is not just that the therapies are better, but that targeted therapies must be given to the right patients," said Schwaederle, who's with the University of California, San Diego School of Medicine's Center for Personalized Cancer Therapy. She will present ... Read more

Related support groups: Cancer, Methotrexate, Breast Cancer, Accutane, Tretinoin, Fluorouracil, Gleevec, Lung Cancer, Colorectal Cancer, Isotretinoin, Claravis, Skin Cancer, Tarceva, Xeloda, Tasigna, Revlimid, BCG, Sprycel, Zytiga, Herceptin

Portrazza Approved for Advanced Lung Cancer

Posted 12 Dec 2015 by Drugs.com

TUESDAY, Nov. 24, 2015 – Portrazza (necitumumab), in combination with two other chemotherapy drugs, has been approved by the U.S. Food and Drug Administration to treat advanced squamous non-small cell lung cancer, the agency said Tuesday in a news release. Lung cancer is the leading cause of cancer death in the United States. More than 221,000 cases are expected to be diagnosed in the U.S. this year, and more than 158,000 people are projected to die from the disease, the FDA said. Portrazza, approved for people who haven't had a previous therapy for squamous NSCLC, is designed to block a protein that's frequently found on such tumors, the agency explained. The drug was evaluated in combination with two other drugs, gemcitabine and cisplatin. Those who took the three-drug combination lived for an average of 11.5 months, compared to 9.9 months among those who took the other two drugs ... Read more

Related support groups: Non-Small Cell Lung Cancer, Necitumumab, Portrazza

FDA Approves Portrazza (necitumumab) for Advanced Squamous Non-Small Cell Lung Cancer

Posted 1 Dec 2015 by Drugs.com

November 24, 2015 – The U.S. Food and Drug Administration today approved Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer. Lung cancer is the leading cause of cancer death in the United States, with an estimated 221,200 new diagnoses and 158,040 deaths in 2015. The most common type of lung cancer, non-small cell lung cancer, is further divided into two main types named for the kinds of cells found in the cancer – squamous cell and non-squamous cell (which includes adenocarcinoma). “Lung cancer tumors can be varied, so treatment options need to be tailored to the specific type of lung cancer in the patient,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncol ... Read more

Related support groups: Non-Small Cell Lung Cancer, Necitumumab, Portrazza

Ask a Question

Further Information

Related Condition Support Groups

Non-Small Cell Lung Cancer

Related Drug Support Groups

Portrazza

Necitumumab Patient Information at Drugs.com